Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Aug;14(8):561-84.
doi: 10.1038/nrd4591.

Combination cancer immunotherapy and new immunomodulatory targets

Kathleen M Mahoney  1 , Paul D Rennert  2 , Gordon J Freeman  3
Affiliations
Review

Combination cancer immunotherapy and new immunomodulatory targets

Kathleen M Mahoney et al. Nat Rev Drug Discov. 2015 Aug.

Abstract

Targeting immune checkpoints such as programmed cell death protein 1 (PD1), programmed cell death 1 ligand 1 (PDL1) and cytotoxic T lymphocyte antigen 4 (CTLA4) has achieved noteworthy benefit in multiple cancers by blocking immunoinhibitory signals and enabling patients to produce an effective antitumour response. Inhibitors of CTLA4, PD1 or PDL1 administered as single agents have resulted in durable tumour regression in some patients, and combinations of PD1 and CTLA4 inhibitors may enhance antitumour benefit. Numerous additional immunomodulatory pathways as well as inhibitory factors expressed or secreted by myeloid and stromal cells in the tumour microenvironment are potential targets for synergizing with immune checkpoint blockade. Given the breadth of potential targets in the immune system, critical questions to address include which combinations should move forward in development and which patients will benefit from these treatments. This Review discusses the leading drug targets that are expressed on tumour cells and in the tumour microenvironment that allow enhancement of the antitumour immune response.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Immunol. 2012 Jan 19;13(2):113-5 - PubMed
    1. Nature. 2014 Nov 27;515(7528):563-7 - PubMed
    1. Immunol Cell Biol. 2014 Mar;92(3):237-44 - PubMed
    1. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7 - PubMed
    1. Mol Cancer Ther. 2010 Oct;9(10):2793-802 - PubMed

Publication types

MeSH terms

LinkOut - more resources